Expert review of respiratory medicine最新文献_第7页

Leveraging immortalized human lung epithelial cell models to study lung cancer: insights from the past and future perspectives. 利用永生化人肺上皮细胞模型研究肺癌：从过去和未来的角度的见解。

Expert review of respiratory medicine Pub Date : 2025-07-09 DOI: 10.1080/17476348.2025.2526777

Mitsuo Sato, Jerry W Shay, John D Minna

引用次数: 0

A clinicians' guide to non-invasive ventilation for exacerbated chronic obstructive pulmonary disease. 加重慢性阻塞性肺疾病无创通气临床医生指南

Expert review of respiratory medicine Pub Date : 2025-07-09 DOI: 10.1080/17476348.2025.2529540

Giulia Panzuti, Gilda Giancotti, Stefano Nava, Maria Laura Vega Pittao

{"title":"A clinicians' guide to non-invasive ventilation for exacerbated chronic obstructive pulmonary disease.","authors":"Giulia Panzuti, Gilda Giancotti, Stefano Nava, Maria Laura Vega Pittao","doi":"10.1080/17476348.2025.2529540","DOIUrl":"10.1080/17476348.2025.2529540","url":null,"abstract":"Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a debilitating condition marked by persistent airflow limitation, leading to increased morbidity and mortality. Acute exacerbations of COPD (AECOPD) can cause rapid deterioration, resulting in hypercapnic respiratory failure and respiratory acidosis. Non-invasive ventilation (NIV) is a key treatment for AECOPD, improving gas exchange, oxygenation, and reducing work of breathing while avoiding the risks of invasive mechanical ventilation (IMV).Areas covered: This review highlights NIV role as a first-line therapy in AECOPD management, discussing its mechanisms, indications, and clinical benefits. Proper patient selection, tailored settings, and careful monitoring are crucial for optimizing outcomes and minimizing complications.Expert opinion: The widespread use of NIV in AECOPD management raises concerns about staff expertise, as success depends on patient selection, ventilator settings, and monitoring. Identifying failure predictors is crucial to prevent delayed intubation and poor outcomes. Research should focus on training, reducing errors, and advancing technology, including Artificial Intelligence-driven automation to improve synchrony. Despite its increased use, especially during COVID-19, progress in staff education and technology remains limited. Enhancing clinician confidence and developing intelligent ventilator algorithms are key, but human expertise remains essential in ensuring effective and life-saving NIV application.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-15"},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment strategies for asthma in women throughout the lifespan - in puberty, pregnancy and menopause. 哮喘在女性整个生命周期的治疗策略-在青春期，怀孕和更年期。

Expert review of respiratory medicine Pub Date : 2025-07-07 DOI: 10.1080/17476348.2025.2530205

Vanessa E Murphy, Joerg Mattes, Esha Joshi

{"title":"Treatment strategies for asthma in women throughout the lifespan - in puberty, pregnancy and menopause.","authors":"Vanessa E Murphy, Joerg Mattes, Esha Joshi","doi":"10.1080/17476348.2025.2530205","DOIUrl":"10.1080/17476348.2025.2530205","url":null,"abstract":"Introduction: Asthma is a common chronic disease which disproportionately affects women. While sex hormones are hypothesized to be involved in changes to asthma during puberty, menstruation, pregnancy and menopause, more research is needed to understand the precise mechanisms involved.Areas covered: This review summarizes the challenges in the treatment of asthma during puberty, pregnancy and menopause. PubMed was searched in the past 10 years for 'puberty/pregnancy/menopause' AND 'asthma.' Non-adherence to asthma treatment is a particular challenge in adolescence and pregnancy. Studies have shown a reduction in the use of inhaled corticosteroids, short acting beta agonists and oral corticosteroids in the first trimester compared to pre-pregnancy. Women perceive a risk of these medications which may contribute to non-adherence during pregnancy. Greater understanding of specific risks of asthma on pregnancy outcomes will assist healthcare professionals in making considered decisions for optimized treatment, including provision of an action plan and correction of inhaler technique. During menopause, new onset asthma can occur, and women with respiratory symptoms should be investigated for an asthma diagnosis so as to receive the required treatment.Expert opinion: A personalized medicine approach which assesses treatable traits and provides holistic care may improve outcomes for women with asthma during puberty, pregnancy and menopause.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of obesity on COPD development: unveiling the hidden risks. 肥胖对慢性阻塞性肺病发展的影响：揭示潜在风险。

Expert review of respiratory medicine Pub Date : 2025-07-06 DOI: 10.1080/17476348.2025.2528945

Ioannis Tomos, Nikolaos Skourlis, Georgia Vourli, Eleni Peppa, Antonia Trichopoulou

{"title":"The impact of obesity on COPD development: unveiling the hidden risks.","authors":"Ioannis Tomos, Nikolaos Skourlis, Georgia Vourli, Eleni Peppa, Antonia Trichopoulou","doi":"10.1080/17476348.2025.2528945","DOIUrl":"10.1080/17476348.2025.2528945","url":null,"abstract":"Background: Obesity represents a frequent comorbidity in chronic obstructive pulmonary disease (COPD); however, its exact role as potential risk factor remains unclear. ur aim is to assess obesity's potential role for COPD development.Research design and methods: The HYDRIA survey has been the first national project on the health of the population in Greece. Data regarding individual characteristics, lifestyle choices, medical history, dietary data and somatometric characteristics were recorded through personal interview in a representative sample of the population.Results: Four thousand eleven men and women aged more than 18 years old were enrolled. COPD is more prevalent in obese people (10.1%; 95% CI: 6.0-14.2%) compared to 5.4%; 95% CI: 4.6-6.2% in non-obese participants. In multivariate analysis, obesity continues to be strongly associated with COPD (OR = 1.76 (95% CI: 1.23-2.53); p = 0.002). Age and smoking are also strong risk factors for COPD. The estimated prevalence of self-reported physician-diagnosed COPD in Greece is 5.9%.Conclusions: Obesity may represent a potential unrevealed risk factor for COPD. Focus on obesity should be included in public health campaigns and preventive programs aiming to decrease the burden of disease and provide the necessary optimal management.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. 索他塞普治疗肺动脉高压的疗效和安全性：随机对照试验的荟萃分析。

Expert review of respiratory medicine Pub Date : 2025-07-06 DOI: 10.1080/17476348.2025.2530201

Mohamad Ershed, Ana Beatriz Nardelli da Silva, Ana Clara Felix de Farias Dos Santos, Danhui Heo, Deivyd Vieira Silva Cavalcante, Jafar Aljazeeri

{"title":"Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials.","authors":"Mohamad Ershed, Ana Beatriz Nardelli da Silva, Ana Clara Felix de Farias Dos Santos, Danhui Heo, Deivyd Vieira Silva Cavalcante, Jafar Aljazeeri","doi":"10.1080/17476348.2025.2530201","DOIUrl":"10.1080/17476348.2025.2530201","url":null,"abstract":"Introduction: To evaluate the efficacy and safety of sotatercept, an activin signaling inhibitor, in pulmonary arterial hypertension (PAH).Methods: We searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) comparing sotatercept versus placebo in PAH. We calculated pooled risk ratios (RR) and mean differences (MD) with their 95% confidence intervals (CI) using a random-effects model. Heterogeneity was assessed with I2 statistics. The GRADE approach was used to assess the certainty of evidence.Results: Three RCTs comprising 601 patients were included. Compared to placebo, sotatercept significantly improved 6-minute walk distance (MD 40.57 m; 95% CI 26.64 to 54.5; p < 0.01), and WHO functional class (RR 2.04; 95% CI 1.53 to 2.7; p < 0.01). Sotatercept reduced pulmonary vascular resistance (MD -233.18 dyn·sec·cm-5; 95% CI -295.84 to -170.52; p < 0.01) and pulmonary artery pressure (MD -14.94 mmHg; 95% CI -19.62 to -10.27; p < 0.01) at study end. No significant differences were observed in all-cause mortality or NT-proBNP levels. Sotatercept was associated with epistaxis, increased hemoglobin, and telangiectasia adverse events.Conclusions: Sotatercept improves exercise capacity, WHO functional class and pulmonary hemodynamics in PAH, with an acceptable safety profile. Long-term studies are needed to confirm sustained benefits.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251032174.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhaled argon for cardiopulmonary resuscitation: current knowledge and future clinical potential. 吸入氩气用于心肺复苏：目前的知识和未来的临床潜力。

IF 2.7

Expert review of respiratory medicine Pub Date : 2025-07-03 DOI: 10.1080/17476348.2025.2528944

Matthias L Riess, Claudius Balzer, Zhu Li, Matthew B Barajas

引用次数: 0

Evaluation of spirometry reference equations among healthy Jordanian adults: a comparative analysis of Jordanian and the Global Lung Initiative equations. 评价健康约旦成年人的肺活量测定参考方程：约旦和全球肺主动方程的比较分析

Expert review of respiratory medicine Pub Date : 2025-07-03 DOI: 10.1080/17476348.2025.2527382

Walid Al-Qerem

{"title":"Evaluation of spirometry reference equations among healthy Jordanian adults: a comparative analysis of Jordanian and the Global Lung Initiative equations.","authors":"Walid Al-Qerem","doi":"10.1080/17476348.2025.2527382","DOIUrl":"10.1080/17476348.2025.2527382","url":null,"abstract":"Background: Accurate spirometry interpretation requires reference equations tailored to the target population. This study evaluated the performance and diagnostic agreement of the locally developed 2018 Jordanian equation and the Global Lung Initiative (GLI) global (2022), GLI-2012 Caucasian, and GLI-2012 Other/Mixed equations among healthy adult Jordanians.Research design and methods: In this cross-sectional study, healthy nonsmoking Jordanian adults aged ≥ 18 years were recruited from various regions. Spirometry and anthropometric data were collected. Each equation's suitability was assessed using mean z-score deviations from zero and standard deviations from one (via t-tests and chi-square tests). Linear and quantile regressions examined relationships between anthropometrics and lung function. Diagnostic agreement was evaluated using Cohen's kappa and frequency of classification shifts.Results: Among 799 participants (400 males), the Jordanian equation showed the best fit, with mean z-scores closest to zero and standard deviations near one. GLI global (2022) and GLI-2012 equations showed significant deviations (p < 0.001), mainly due to age-related bias. Agreement was highest between GLI global (2022) and GLI-2012 Other/Mixed; GLI-2012 Caucasian classified the fewest as normal.Conclusion: The Jordanian equation provided better accuracy than GLI equations. Its use in practice may reduce misclassification and improve respiratory disease management, underscoring the value of population-specific standards.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to letter to the editor: 'roles of vitamins and nutrition in obstructive sleep apnea'. 回复给编辑的信：“维生素和营养在阻塞性睡眠呼吸暂停中的作用”。

Expert review of respiratory medicine Pub Date : 2025-07-01 Epub Date: 2025-05-08 DOI: 10.1080/17476348.2025.2499295

Kostas Archontogeorgis, Evangelia Nena, Paschalis Steiropoulos

引用次数: 0

The pathogenesis of ventilator-associated pneumonia: old and new mechanisms. 呼吸机相关性肺炎的发病机制：新旧机制。

Expert review of respiratory medicine Pub Date : 2025-07-01 Epub Date: 2025-04-16 DOI: 10.1080/17476348.2025.2493366

Arnau Ulsamer, Sergio Bonilla, Xosé Pérez-Fernández, Jordi Rello, Joan Sabater-Riera

{"title":"The pathogenesis of ventilator-associated pneumonia: old and new mechanisms.","authors":"Arnau Ulsamer, Sergio Bonilla, Xosé Pérez-Fernández, Jordi Rello, Joan Sabater-Riera","doi":"10.1080/17476348.2025.2493366","DOIUrl":"10.1080/17476348.2025.2493366","url":null,"abstract":"Introduction: Ventilator-associated pneumonia (VAP), defined as a lung infection that occurs in patients after 48 hours on mechanical ventilation, is among the most frequently found nosocomial infections in intensive care units around the world and is associated with increased morbidity, mortality, and economic burden.Areas covered: We review the classical mechanisms of VAP development and explore more recent ones, such as dysbiosis, which has changed our view of the pathogenesis of the disease; whereas in the past the lower respiratory tract was classically considered a sterile organ, the use of new diagnostic techniques has shown that the lungs of healthy humans are inhabited by a large, dynamic ecosystem of microorganisms. Dysbiosis is the disruption of this ecosystem and is a key factor in the development of VAP. Recent findings have demonstrated that host immunity is microbiome-regulated and, consequently, is profoundly affected by dysbiosis. In this paper the significance of the microbiome-immunity crosstalk in the pathophysiology of VAP will be discussed.Expert opinion: A deeper understanding of mechanisms of VAP pathogenesis should help to devise new preventive, diagnostic and therapeutic strategies for reducing the incidence of this condition and for improving patient prognosis.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"655-671"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent discoveries from clinical trials: why opioids should not be used for dyspnea management in COPD. 临床试验的最新发现：为什么阿片类药物不应用于慢性阻塞性肺病的呼吸困难治疗。

Expert review of respiratory medicine Pub Date : 2025-07-01 Epub Date: 2025-04-23 DOI: 10.1080/17476348.2025.2494643

Nicholas T Vozoris

{"title":"Recent discoveries from clinical trials: why opioids should not be used for dyspnea management in COPD.","authors":"Nicholas T Vozoris","doi":"10.1080/17476348.2025.2494643","DOIUrl":"10.1080/17476348.2025.2494643","url":null,"abstract":"Introduction: Chronic breathlessness among persons with chronic obstructive pulmonary disease (COPD) is a distressing and limiting symptom and a substantial management challenge for healthcare practitioners. Historically, multiple professional respiratory societies have encouraged the prescription of opioid drugs as a therapeutic intervention for chronic breathlessness. However, in 2024, the European Respiratory Society (ERS) published clinical practice guidelines that markedly departed from such traditional recommendations and stated that opioids should not be used for chronic breathlessness.Areas covered: This manuscript will review recently published, well-designed, randomized controlled trials (literature was searched on PubMed from January 2020 to January 2025) that evaluated the efficacy of oral opioids for chronic breathlessness in persons with COPD and which influenced the new position adopted by ERS in 2024.Expert opinion: Recent, well-designed, adequately powered clinical trials consistently demonstrate that oral opioids are not effective at reducing chronic breathlessness (nor at improving overall quality of life, functional status or exercise tolerance) amongst individuals with advanced COPD. Other professional respiratory societies need to consider and potentially embrace the new ERS position on opioids for dyspnea in COPD, so as to guide members away from an unhelpful, and in some cases harmful, management paradigm.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"673-678"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0